Detalhe da pesquisa
1.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Blood
; 140(17): 1845-1857, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917453
2.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol
; 41(26): 4236-4246, 2023 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379495